ANTIMICROBIAL THERAPEUTICS MARKET ANALYSIS

Antimicrobial Therapeutics Market, By Drug Class (Antibacterials, Antivirals, Antifungals, Antiparasitics), By Route of Administration (Oral, Topical, Injectable, Others), By Disease Indication (Respiratory Infections, Urinary Tract Infections (UTIs), Skin and Soft Tissue infections, Sexually Transmitted Infections (STIs), Gastrointestinal Infections, Central Nervous System Infections and others, Sexually Transmitted Infections (STIs), Gastrointestinal Infections, Central Nervous System Infections, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East)

Recent Developments

New product launches/approval

In August 2020, Alembic Pharmaceuticals Limited, a pharmaceutical company, announced that the company had received approval from the U.S. FDA for its anti-fungal Tavaborole Topical Solution. Tavaborole Topical Solution is indicated for the treatment of onychomycosis of the toenails.
In June 2021, Mankind Pharma, a pharmaceutical company, announced the launch of Posacoazole Gastro resistant tablets used to treat black fungus.

Acquisition

On January 24, 2023, Sandoz International GmbH, the global leader in off-patent (generic and biosimilar) medicines, signed an agreement to acquire worldwide product rights for the leading systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas Pharma Inc., a Japan-based pharmaceutical company.
In 2021, Pfizer Inc. announced that it had acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals, Inc’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.